(Q35212620)

7 August 2017

title

A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma (English)

1 reference

7 August 2017

1 reference

Christian H. Ottensmeier

object named as

C Ottensmeier

12

0 references

author name string

S O'Day

1

1 reference

7 August 2017

A Pavlick

2

1 reference

7 August 2017

C Loquai

3

1 reference

7 August 2017

D Lawson

4

1 reference

7 August 2017

R Gutzmer

5

1 reference

7 August 2017

J Richards

6

1 reference

7 August 2017

D Schadendorf

7

1 reference

7 August 2017

J A Thompson

8

1 reference

7 August 2017

R Gonzalez

9

1 reference

7 August 2017

U Trefzer

10

1 reference

7 August 2017

P Mohr

11

1 reference

7 August 2017

D Chao

13

1 reference

7 August 2017

B Zhong

14

1 reference

7 August 2017

C J de Boer

15

1 reference

7 August 2017

C Uhlar

16

1 reference

7 August 2017

D Marshall

17

1 reference

7 August 2017

M E Gore

18

1 reference

7 August 2017

Z Lang

19

1 reference

7 August 2017

W Hait

20

1 reference

7 August 2017

P Ho

21

1 reference

7 August 2017

CNTO 95 Investigators

22

1 reference

7 August 2017

language of work or name

English

0 references

publication date

12 July 2011

1 reference

British Journal of Cancer

7 August 2017

published in

1 reference

7 August 2017

volume

105

1 reference

7 August 2017

issue

3

1 reference

7 August 2017

page(s)

346-352

1 reference

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

7 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172894

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172894

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172894

13 July 2018

Angiogenesis in melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172894

Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172894

Direct targeting of alphavbeta3 integrin on tumor cells with a monoclonal antibody, Abegrin

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172894

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172894

Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172894

CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172894

Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172894

13 July 2018

Cancer statistics, 2004

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172894

Alpha v integrin inhibitors and cancer therapy.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172894

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172894

Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172894

Molecular role(s) for integrins in human melanoma invasion

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172894

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172894

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172894

Integrin alpha(v)beta3 promotes M21 melanoma growth in human skin by regulating tumor cell survival

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172894

The prognostic significance of tumor vascularity in intermediate-thickness (0.76-4.0 mm thick) skin melanoma. A quantitative histologic study

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172894

Involvement of integrin alpha V gene expression in human melanoma tumorigenicity

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172894

Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172894

26 September 2018

Cancer statistics, 1995.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172894

A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172894

Interleukin-2: clinical applications

26 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FBJC.2011.183

Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A)

21 January 2018

1 reference

12 December 2020

Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression

1 reference

12 December 2020

Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis

1 reference

12 December 2020

1 reference

12 December 2020

Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.2011.183

1 reference

7 August 2017

1 reference

7 August 2017

1 reference